{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:56:24Z","timestamp":1783115784612,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10072-025-08055-4","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:36:37Z","timestamp":1739993797000},"page":"2737-2746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-0306","authenticated-orcid":false,"given":"Meral","family":"Sefero\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilge Piri","family":"\u00c7\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dclgen Yalaz","family":"Tekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Av\u015far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Yi\u011fit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali \u00d6zhan","family":"S\u0131vac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih","family":"T\u00fct\u00fcnc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihat","family":"Uzunk\u00f6pr\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye\u015fim","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl\u015fen Akman","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Sa\u011fduyu","family":"Kocaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksel","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"8055_CR1","unstructured":"Sabat\u00e9 E and Sabat\u00e9 E (2003) Adherence to long-term therapies: evidence for action. World Health Organization."},{"key":"8055_CR2","doi-asserted-by":"crossref","unstructured":"Finkelsztejn A (2014) Multiple sclerosis: overview of disease-modifying agents. Perspectives in medicinal chemistry 6 PMC S13213.","DOI":"10.4137\/PMC.S13213"},{"issue":"1","key":"8055_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.msard.2014.09.214","volume":"4","author":"B Cohen","year":"2015","unstructured":"Cohen B et al (2015) Therapy optimization in multiple sclerosis: a cohort study of therapy adherence and risk of relapse. Multiple Sclerosis Related Disorders 4(1):75\u201382","journal-title":"Multiple Sclerosis Related Disorders"},{"issue":"1","key":"8055_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","volume":"28","author":"H Tan","year":"2011","unstructured":"Tan H et al (2011) Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 28(1):51\u201361","journal-title":"Adv Ther"},{"issue":"1","key":"8055_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","volume":"18","author":"V Devonshire","year":"2011","unstructured":"Devonshire V et al (2011) The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 18(1):69\u201377","journal-title":"Eur J Neurol"},{"issue":"4","key":"8055_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.nrleng.2015.03.003","volume":"30","author":"A Saiz","year":"2015","unstructured":"Saiz A, Mora S, Blanco J (2015) Treatment compliance with first line disease-modifying therapies in patients with multiple sclerosis. Compliance study Neurolog\u00eda (English Edition) 30(4):214\u2013222","journal-title":"Compliance study Neurolog\u00eda (English Edition)"},{"key":"8055_CR7","first-page":"629","volume":"5","author":"A Ri\u00f1on","year":"2011","unstructured":"Ri\u00f1on A et al (2011) The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence 5:629","journal-title":"Patient Prefer Adherence"},{"key":"8055_CR8","doi-asserted-by":"crossref","unstructured":"Menzin J et al (2013) Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Managed Care Pharmacy 19(1 Supp A):S24-S40.","DOI":"10.18553\/jmcp.2013.19.s1.S24"},{"key":"8055_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","volume":"8","author":"C Evans","year":"2016","unstructured":"Evans C et al (2016) Adherence and persistence to drug therapies for multiple sclerosis: a population-based study. Multiple Sclerosis and Related Disorders 8:78\u201385","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"4","key":"8055_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/1352458516657440","volume":"23","author":"KA McKay","year":"2017","unstructured":"McKay KA et al (2017) Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Mult Scler J 23(4):588\u2013596","journal-title":"Mult Scler J"},{"issue":"2","key":"8055_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","volume":"30","author":"SC Steinberg","year":"2010","unstructured":"Steinberg SC et al (2010) Impact of adherence to interferons in the treatment of multiple sclerosis. Clin Drug Investig 30(2):89\u2013100","journal-title":"Clin Drug Investig"},{"issue":"4","key":"8055_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00415-009-0096-y","volume":"256","author":"K Treadaway","year":"2009","unstructured":"Treadaway K et al (2009) Factors that influence adherence with disease-modifying therapy in MS. J Neurol 256(4):568\u2013576","journal-title":"J Neurol"},{"issue":"3","key":"8055_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jpainsymman.2019.06.013","volume":"58","author":"M Wilski","year":"2019","unstructured":"Wilski M et al (2019) Perception of multiple sclerosis impact and treatment efficacy beliefs: mediating effect of patient\u2019s illness and Self-Appraisals. J Pain Symptom Manage 58(3):437\u2013444","journal-title":"J Pain Symptom Manage"},{"key":"8055_CR14","doi-asserted-by":"crossref","unstructured":"Bunul SD (2023) Treatment Adherence in Multiple Sclerosis: The Effect of Drug Administration Methods and Neuropsychiatric Comorbidities.\u00a0Bosphorus Medical Journal\/Bo\u011fazi\u00e7i T\u0131p Dergisi\u00a010(4).","DOI":"10.14744\/bmj.2023.43265"},{"key":"8055_CR15","doi-asserted-by":"crossref","unstructured":"Corallo F et al (2019) Therapeutic adherence and coping strategies in patients with multiple sclerosis: an observational study. Med 98(29).","DOI":"10.1097\/MD.0000000000016532"},{"key":"8055_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/PPA.S108121","volume":"10","author":"PJ Jongen","year":"2016","unstructured":"Jongen PJ et al (2016) Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Prefer Adherence 10:909","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"8055_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40120-015-0037-x","volume":"4","author":"J Theodore Phillips","year":"2015","unstructured":"Theodore Phillips J et al (2015) Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study. Neurology and therapy 4(2):137\u2013146","journal-title":"Neurology and therapy"},{"issue":"5","key":"8055_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3111\/13696998.2015.1134546","volume":"19","author":"NP Thomas","year":"2016","unstructured":"Thomas NP et al (2016) The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. J Med Econ 19(5):497\u2013505","journal-title":"J Med Econ"},{"issue":"2","key":"8055_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1017\/S0317167100013755","volume":"40","author":"M Kremenchutzky","year":"2013","unstructured":"Kremenchutzky M, Walt L (2013) Perceptions of health status in multiple sclerosis patients and their doctors. Can J Neurol Sci 40(2):210\u2013218","journal-title":"Can J Neurol Sci"},{"issue":"7094","key":"8055_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/bmj.314.7094.1580","volume":"314","author":"P Rothwell","year":"1997","unstructured":"Rothwell P et al (1997) Doctors and patients don\u2019t agree: cross sectional study of patients\u2019 and doctors\u2019 perceptions and assessments of disability in multiple sclerosis. BMJ 314(7094):1580","journal-title":"BMJ"},{"key":"8055_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/PPA.S291485","volume":"15","author":"E Neter","year":"2021","unstructured":"Neter E et al (2021) Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status. Patient Prefer Adherence 15:939","journal-title":"Patient Prefer Adherence"},{"key":"8055_CR22","doi-asserted-by":"publisher","first-page":"103005","DOI":"10.1016\/j.msard.2021.103005","volume":"52","author":"S Demir","year":"2021","unstructured":"Demir S et al (2021) A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey. Mult Scler Relat Disord 52:103005","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"8055_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJMp1109283","volume":"366","author":"MJ Barry","year":"2012","unstructured":"Barry MJ, Edgman-Levitan S (2012) Shared decision making\u2013pinnacle of patient-centered care. N Engl J Med 366(9):780\u2013781","journal-title":"N Engl J Med"},{"issue":"17 Suppl","key":"8055_CR24","first-page":"s332","volume":"19","author":"LE Happe","year":"2013","unstructured":"Happe LE (2013) Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice. Am J Manag Care 19(17 Suppl):s332\u2013s342","journal-title":"Am J Manag Care"},{"issue":"9","key":"8055_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12325-011-0054-9","volume":"28","author":"R Halpern","year":"2011","unstructured":"Halpern R et al (2011) Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 28(9):761\u2013775","journal-title":"Adv Ther"},{"issue":"2","key":"8055_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/ane.12705","volume":"136","author":"UK Zettl","year":"2017","unstructured":"Zettl UK et al (2017) Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis. Acta Neurol Scand 136(2):116\u2013121","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"8055_CR27","first-page":"639","volume":"27","author":"NJ Engmann","year":"2021","unstructured":"Engmann NJ et al (2021) Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm 27(5):639\u2013649","journal-title":"J Manag Care Spec Pharm"},{"key":"8055_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.863105","volume":"13","author":"MS Weber","year":"2022","unstructured":"Weber MS et al (2022) Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study. Front Neurol 13:863105","journal-title":"Front Neurol"},{"key":"8055_CR29","doi-asserted-by":"publisher","first-page":"103915","DOI":"10.1016\/j.msard.2022.103915","volume":"63","author":"R Alonso","year":"2022","unstructured":"Alonso R et al (2022) Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America. Mult Scler Relat Disord 63:103915","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"8055_CR30","doi-asserted-by":"publisher","first-page":"e35600","DOI":"10.1371\/journal.pone.0035600","volume":"7","author":"O Fernandez","year":"2012","unstructured":"Fernandez O et al (2012) Adherence to interferon beta-1b treatment in patients with multiple sclerosis in Spain. PLoS ONE 7(5):e35600","journal-title":"PLoS ONE"},{"key":"8055_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/PPA.S118107","volume":"11","author":"M Munsell","year":"2017","unstructured":"Munsell M et al (2017) An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Prefer Adherence 11:55\u201362","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"8055_CR32","first-page":"1394","volume":"22","author":"L Higuera","year":"2016","unstructured":"Higuera L, Carlin CS, Anderson S (2016) Adherence to Disease-Modifying Therapies for Multiple Sclerosis. J Manag Care Spec Pharm 22(12):1394\u20131401","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"8055_CR33","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1038\/s41598-019-40283-5","volume":"9","author":"N Frahm","year":"2019","unstructured":"Frahm N, Hecker M, Zettl UK (2019) Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors. Sci Rep 9(1):3743","journal-title":"Sci Rep"},{"issue":"6","key":"8055_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/ane.13301","volume":"142","author":"S Lahdenpera","year":"2020","unstructured":"Lahdenpera S et al (2020) Medication adherence\/persistence among patients with active multiple sclerosis in Finland. Acta Neurol Scand 142(6):605\u2013612","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"8055_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4065\/mcp.2010.0575","volume":"86","author":"MT Brown","year":"2011","unstructured":"Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86(4):304\u2013314","journal-title":"Mayo Clin Proc"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08055-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:24:43Z","timestamp":1747376683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08055-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["8055"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08055-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with ethical guidelines and approved by the relevant ethical review board. Ethical approval for the study was obtained from the university ethics committee (Bulent Ecevit University Local Ethics Committee number: 2021\/06). All participants provided informed consent prior to their inclusion in the study. The authors have no conflicts of interest to declare. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors of this study state that there is no financial interest or personal relationships that could have influenced the findings of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}